Predictive Modeling of Drug Response in Non-Hodgkin’s Lymphoma

We combine mathematical modeling with experiments in living mice to quantify the relative roles of intrinsic cellular vs. tissue-scale physiological contributors to chemotherapy drug resistance, which are difficult to understand solely through experimentation. Experiments in cell culture and in mice with drug-sensitive (Eµ-myc/Arf-/-) and drug-resistant (Eµ-myc/p53-/-) lymphoma cell lines were conducted to calibrate and validate a mechanistic mathematical model. Inputs to inform the model include tumor drug transport characteristics, such as blood volume fraction, average geometric mean blood vessel radius, drug diffusion penetration distance, and drug response in cell culture. Model results show that the drug response in mice, represented by the fraction of dead tumor volume, can be reliably predicted from these inputs. Hence, a proof-of-principle for predictive quantification of lymphoma drug therapy was established based on both cellular and tissue-scale physiological contributions. We further demonstrate that, if the in vitro cytotoxic response of a specific cancer cell line under chemotherapy is known, the model is then able to predict the treatment efficacy in vivo. Lastly, tissue blood volume fraction was determined to be the most sensitive model parameter and a primary contributor to drug resistance.

[1]  Mauro Ferrari,et al.  Transport properties of pancreatic cancer describe gemcitabine delivery and response. , 2014, The Journal of clinical investigation.

[2]  V. Seshan,et al.  Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P K Maini,et al.  A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin’s lymphoma: Investigation of the current protocol through theoretical modelling results , 2005, Bulletin of mathematical biology.

[4]  Nikolaos K. Uzunoglu,et al.  A spatiotemporal, patient individualized simulation model of solid tumor response to chemotherapy in vivo: the paradigm of glioblastoma multiforme treated by temozolomide , 2006, IEEE Transactions on Biomedical Engineering.

[5]  I. Tannock,et al.  Drug resistance and the solid tumor microenvironment. , 2007, Journal of the National Cancer Institute.

[6]  I. Glauche,et al.  Pathogenesis, treatment effects, and resistance dynamics in chronic myeloid leukemia - insights from mathematical model analyses , 2007, Journal of Molecular Medicine.

[7]  M. Perry The Chemotherapy Source Book , 1992, Annals of Internal Medicine.

[8]  G. Melillo,et al.  Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia , 2012, Nature Reviews Clinical Oncology.

[9]  M. Meyer-Hermann,et al.  Are T cells at the origin of B cell lymphomas? , 2007, Journal of theoretical biology.

[10]  P. Comoglio,et al.  Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.

[11]  M. Chaplain,et al.  A mathematical model of breast cancer development, local treatment and recurrence. , 2007, Journal of theoretical biology.

[12]  Jana L. Gevertz,et al.  Computational Modeling of Tumor Response to Vascular-Targeting Therapies—Part I: Validation , 2011, Comput. Math. Methods Medicine.

[13]  Società Italiana di Emaferesi Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis , 2001 .

[14]  Zhihui Wang,et al.  Cross-scale, cross-pathway evaluation using an agent-based non-small cell lung cancer model , 2009, Bioinform..

[15]  R. Crownover Hematology/Oncology Clinics of North America: Preface , 1999 .

[16]  C. Dang,et al.  Biology and treatment of Burkitt's lymphoma , 2007, Current opinion in hematology.

[17]  Min Wu,et al.  The effect of interstitial pressure on tumor growth: coupling with the blood and lymphatic vascular systems. , 2013, Journal of theoretical biology.

[18]  M. Ogura,et al.  Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer‐cell malignancies , 2012, Cancer science.

[19]  I. Tannock,et al.  Drug penetration in solid tumours , 2006, Nature Reviews Cancer.

[20]  ffalourd Mathematics and algorithms , 2017 .

[21]  Joon-Kee Yoon,et al.  Unexpected dissemination patterns in lymphoma progression revealed by serial imaging within a murine lymph node. , 2012, Cancer research.

[22]  Zhihui Wang,et al.  Development of a sampling-based global sensitivity analysis workflow for multiscale computational cancer models. , 2014, IET systems biology.

[23]  Mauro Ferrari,et al.  Prediction of drug response in breast cancer using integrative experimental/computational modeling. , 2009, Cancer research.

[24]  M. Westphal,et al.  Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. , 2001, Cancer research.

[25]  S. Goldman,et al.  Hematology/Oncology Clinics of North America , 2020, Hematology/Oncology Clinics of North America.

[26]  M. Bodnar,et al.  About a generalized model of lymphoma , 2012 .

[27]  Jason M. Graham,et al.  A spatial model of tumor-host interaction: application of chemotherapy. , 2008, Mathematical biosciences and engineering : MBE.

[28]  O. O’Connor,et al.  New drugs for the treatment of lymphoma. , 2008, Hematology/oncology clinics of North America.

[29]  T. Grogan,et al.  Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. , 1989, Journal of the National Cancer Institute.

[30]  Vittorio Cristini,et al.  Mechanistic modeling identifies drug-uptake history as predictor of tumor drug resistance and nano-carrier-mediated response. , 2013, ACS nano.

[31]  Sharon E Ungersma,et al.  Vessel imaging with viable tumor analysis for quantification of tumor angiogenesis , 2010, Magnetic resonance in medicine.

[32]  K. Savage,et al.  Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Vittorio Cristini,et al.  Mechanistic patient-specific predictive correlation of tumor drug response with microenvironment and perfusion measurements , 2013, Proceedings of the National Academy of Sciences.

[34]  Ken Ito,et al.  An Integrated Computational/Experimental Model of Lymphoma Growth , 2013, PLoS Comput. Biol..

[35]  B Ribba,et al.  A multiscale mathematical model of avascular tumor growth to investigate the therapeutic benefit of anti-invasive agents. , 2006, Journal of theoretical biology.

[36]  Vittorio Cristini,et al.  Three-dimensional multispecies nonlinear tumor growth-II: Tumor invasion and angiogenesis. , 2010, Journal of theoretical biology.

[37]  P. Maini,et al.  MODELLING THE RESPONSE OF VASCULAR TUMOURS TO CHEMOTHERAPY: A MULTISCALE APPROACH , 2006 .

[38]  H. Frieboes,et al.  An integrated computational/experimental model of tumor invasion. , 2006, Cancer research.

[39]  Soyoung Lee,et al.  A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy , 2002, Cell.

[40]  Karen M Page,et al.  Mathematical models of the fate of lymphoma B cells after antigen receptor ligation with specific antibodies. , 2006, Journal of theoretical biology.

[41]  Vittorio Cristini,et al.  Predictions of tumour morphological stability and evaluation against experimental observations , 2011, Journal of The Royal Society Interface.

[42]  Zhihui Wang,et al.  Cross-scale sensitivity analysis of a non-small cell lung cancer model: Linking molecular signaling properties to cellular behavior , 2007, Biosyst..

[43]  J. Teruya-Feldstein,et al.  The Schedule-Dependent Effects of the Novel Antifolate Pralatrexate and Gemcitabine Are Superior to Methotrexate and Cytarabine in Models of Human Non-Hodgkin's Lymphoma , 2006, Clinical Cancer Research.

[44]  Mauro Ferrari,et al.  Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation , 2008, Journal of mathematical biology.

[45]  Society of magnetic resonance in medicine , 1990 .

[46]  Zhuang Liu,et al.  High-resolution, serial intravital microscopic imaging of nanoparticle delivery and targeting in a small animal tumor model. , 2013, Nano today.

[47]  Dirk Hasenclever,et al.  Modelling Lymphoma Therapy and Outcome , 2014, Bulletin of mathematical biology.

[48]  Mary E. Edgerton,et al.  A Novel, Patient-Specific Mathematical Pathology Approach for Assessment of Surgical Volume: Application to Ductal Carcinoma in situ of The Breast , 2011, Analytical cellular pathology.

[49]  J. Kuruvilla,et al.  Relapsed and refractory aggressive NHL: time for a change. , 2013, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

[50]  Vittorio Cristini,et al.  Impact of Diffusion Barriers to Small Cytotoxic Molecules on the Efficacy of Immunotherapy in Breast Cancer , 2013, PloS one.

[51]  S. Lowe,et al.  Tumor suppression by Ink4a-Arf: progress and puzzles. , 2003, Current opinion in genetics & development.

[52]  Carlo Giussani,et al.  Combinatorial Administration of Molecules That Simultaneously Inhibit Angiogenesis and Invasion Leads to Increased Therapeutic Efficacy in Mouse Models of Malignant Glioma , 2004, Clinical Cancer Research.

[53]  Lothar Lilge,et al.  The Distribution of the Anticancer Drug Doxorubicin in Relation to Blood Vessels in Solid Tumors , 2005, Clinical Cancer Research.

[54]  Mauro Ferrari,et al.  Morphologic Instability and Cancer Invasion , 2005, Clinical Cancer Research.